Opinion: More industry-stakeholders play blame game for high drug costs March 22, 2017By Devon Herrick PhDOur policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs. Five pharmacy regulations health execs must keep on their radars in 2017 March 18, 2017By Kenneth MaxikHere are five critical regulations that executives can begin to prepare for today. What more transparency at the FDA means for health executives March 18, 2017By Tracey WalkerResearchers create a set of recommendations for transparency at the agency in five principal areas. More resources needed for medication-assisted treatment March 13, 2017By Tracey WalkerInclude medication-assisted treatment high on the list of clinical tools used to treat opioid addiction. ACA reform must preserve mental health pharmacy access March 12, 2017By John FigueroaACA repeal or replacement must focus on how to preserve mental health services and pharmacy access. Cannabinoid-based drug pipeline shows promiseNew treatment indications are under investigation for the use of cannabinoid-based drugs. New strategies for managing drug spend: RA, Cancer, Hep C March 04, 2017By Mari EdlinThe proliferation of specialty drugs has prompted new techniques for keeping costs in tow. Cannabinoid-based drug pipeline grows: 4 ways to prepareNew treatment indications are under investigation for the use of cannabinoid-based drugs. Are you ready? Payers to pharma: Here’s what we’re missing in hep C drugs February 17, 2017By Tracey WalkerA Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment. Express Scripts’ 2016 Drug Trend Report: 7 things to know February 13, 2017By Tracey WalkerReport highlights spending trends in key areas, including specialty medications, oncology, diabetes, and inflammatory conditions.